TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06017141
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06017141
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via inhalation
Study: NCT04540848
Drug: Group A (Exparel plus supraclavicular block)
Normalized name: meningococcal group A polysaccharide
DrugBank: Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen (DB10798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 20 cc (266 mg) of Exparel injected in the distal radius area and a supraclavicular block in the recovery room.The supraclavicular blocks will be ultrasound guided and consist of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket.
Study: NCT04540848
Drug: Group B (Bupivacaine HCL plus supraclavicular block)
Normalized name: meningococcal group B vaccine
DrugBank: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen (DB10284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 20 cc of Bupivacaine 0.25% (50mg) in the distal radius area.In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket.
Study: NCT04540848
Drug: Group C(supraclavicular block only)
Normalized name: meningococcal group C polysaccharide
DrugBank: Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (DB10799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket.
Study: NCT05711628
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05738538
Drug: ziftomenib
Normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06497985
Drug: Tucidinostat
Normalized name: tucidinostat
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 30mg orally BIW
Study: NCT06497985
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenously (IV) Q3W
Study: NCT06497985
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg/kg intravenously (IV) Q3W
Study: NCT06497985
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg orally QD
Study: NCT06504875
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg ivd D1
Study: NCT06504875
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin 2 100IU HD,QOD d1-d14
Study: NCT06504875
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130mg/m2 ivd, d1
Study: NCT00270114
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04879134
Drug: Apomorphine Injectable Solution
Normalized name: apomorphine Injectable Solution
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo
Study: NCT05427721
Drug: Thymol
Normalized name: Thymol
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg each 8 hours for 90 days
Study: NCT05675800
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin administered with psychological support
Study: NCT04698434
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: each group was given a single intravenous dose of the corresponding esketamine.
Study: NCT04290442
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ropivacaine 0.5% will be use in the block
Study: NCT00237367
Drug: rabeprazole and pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05284175
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib, orally, 50 mg QD
Study: NCT04882462
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks
Study: NCT04882462
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;
Study: NCT04882462
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks
Study: NCT06268769
Drug: Tacrolimus Pill
Normalized name: tacrolimus Pill
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Study: NCT06268769
Drug: Tacrolimus capsule
Normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Study: NCT05392764
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once-daily oral empagliflozin 10 mg
Study: NCT04779177
Drug: Lumateperone 42 mg
Normalized name: lumateperone 42 MG
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone 42 mg, oral administration
Study: NCT04779177
Drug: Lumateperone 28 mg
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone 28 mg, oral administration
Study: NCT06045806
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06045806
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04578613
Drug: Chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
Study: NCT04578613
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
Study: NCT05273359
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
Study: NCT04629651
Drug: Captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, to be administered per the dose escalation scheme.
Study: NCT04296942
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg by mouth weekly (RP2D) administered by patient on Days 1, 8 and 15 of each cycle.
Study: NCT06102174
Drug: Active
Normalized name: Active
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sisunatovir
Study: NCT05504694
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion.
Study: NCT04998981
Drug: Fenofibrate 200 mg capsule
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 200 mg capsule once daily
Study: NCT04088188
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04088188
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04088188
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04088188
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06645249
Drug: Amiodarone (Antiarrhythmic drug)
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring
Study: NCT06067490
Drug: RC1416(SAD)
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
Study: NCT06641076
Drug: Sonelokimab
Normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment, parallel-group
Study: NCT06525246
Drug: ONO-7475
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose, once daily
Study: NCT06525246
Drug: Osimertinib Mesylate
Normalized name: Osimertinib Mesylate
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose, once daily
Study: NCT00437723
Drug: epoetin beta [NeoRecormon]
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: At a dose to achieve and maintain an Hb level of 120-135g/dL.
Study: NCT06584461
Drug: Lidocaine (drug)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine, administered once during the induction of anesthesia.
Study: NCT06584461
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV placebo (normal saline), administered once during the induction of anesthesia.
Study: NCT05876585
Drug: Ondansetron 8 mg ampoule
Normalized name: ondansetron 8 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug
Study: NCT05876585
Drug: Metoclopramide 10 mg ampoule
Normalized name: metoclopramide 10 MG
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparator drug
Study: NCT04515797
Drug: Glecaprevir and Pibrentasvir
Normalized name: glecaprevir and pibrentasvir
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 weeks of treatment starting within 24 hrs of kidney transplant
Study: NCT06306274
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (0,1%) ointment
Study: NCT06268301
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide oral suspension
Study: NCT06039163
Drug: HH-120
Normalized name: HH-009
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.
Study: NCT05683301
Drug: Amlodipine + Perindopril
Normalized name: amlodipine / perindopril
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single pill combination of dual antihypertensive agent
Study: NCT05877547
Drug: Efinopegdutide
Normalized name: Efinopegdutide
DrugBank: Efinopegdutide (DB15077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
Study: NCT05877547
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
Study: NCT05053425
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given po.
Study: NCT05053425
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given sc.
Study: NCT05053425
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given ivgtt.
Study: NCT05053425
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given sc or ivgtt.
Study: NCT05053425
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given ivgtt.
Study: NCT03934905
Drug: sulforaphane
Normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
Study: NCT05705167
Drug: Plitidepsin
Normalized name: plitidepsin
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion over 60-minutes
Study: NCT06583837
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib was administrated for 12 weeks
Study: NCT04939428
Drug: Molnupiravir
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Four molnupiravir 200 mg capsules taken by mouth.
Study: NCT06233630
Drug: Ropivacaine 0.2% Injectable Solution ESPB
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided erector spinae plane block (ESPB) - L2 level, unilateral
Study: NCT06233630
Drug: Ropivacaine 0.2% Injectable Solution iPACK+ACB
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided iPACK block + Adductor Canal Block
Study: NCT05905055
Drug: co-administration of cefepime and nacubactam
Normalized name: cefepime and amikacin
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
Study: NCT05905055
Drug: co-administration of aztreonam and nacubactam
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
Study: NCT05905055
Drug: BAT
Normalized name: RibaTab
DrugBank: Equine Botulinum Neurotoxin E Immune FAB2 (DB13897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of BAT will be based per site's standard of care
Study: NCT06401005
Drug: Cadonilimab (AK104)
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8Gy\*3 SBRT to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK104 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of doxorubicin 50mg/m2 (Q3W) + cyclophosphamide 600mg/m2 (Q3W) were administered, followed by four cycles of sequential albumin paclitaxel (125 mg/m2, d1, d8) and carboplatin (AUC=6, d1, Q3W) for 4 cycles. Postoperative completion of 9 cycles of immunotherapy was continued ± the need for postoperative adjuvant radiotherapy was confirmed based on the patient's preoperative status.
Study: NCT06301399
Drug: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy
Normalized name: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.
Study: NCT04956692
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV injection
Study: NCT04956692
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04956692
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT04956692
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04956692
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT05379686
Drug: GlucaGen
Normalized name: GlucaGen
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 ug glucagon will be administered to the participants before exercise.
Study: NCT04940546
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mode of administration: Intravenously
Study: NCT04940546
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mode of administration: Intravenously
Study: NCT04940546
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mode of administration: Intravenously
Study: NCT05502731
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.
Study: NCT05502731
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.
Study: NCT05990881
Drug: Botulinum toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive an injection of Botulinum toxin.
Study: NCT05515796
Drug: Terelizumab (aka Tislelizumab)
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
Study: NCT05515796
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
Study: NCT06119529
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05922436
Drug: QLG2071
DrugBank: G207 (DB05827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT05490082
Drug: Mirabegron, Propevirine, Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy comparison
Study: NCT05717335
Drug: TachoSil
Normalized name: TachoSil
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.